|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1159211098 |
| 003 |
OCoLC |
| 005 |
20231120010458.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
200622t20202020maua ob 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d OPELS
|d EBLCP
|d OCLCF
|d YDXIT
|d OCLCO
|d UKMGB
|d N$T
|d TEF
|d OCLCA
|d OCLCO
|d OCLCQ
|d COM
|d OCL
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBC072204
|2 bnb
|
| 016 |
7 |
|
|a 019811087
|2 Uk
|
| 019 |
|
|
|a 1201804423
|
| 020 |
|
|
|a 9780128211199
|q (electronic book)
|
| 020 |
|
|
|a 0128211199
|q (electronic book)
|
| 020 |
|
|
|z 9780128211182
|
| 020 |
|
|
|z 0128211180
|
| 035 |
|
|
|a (OCoLC)1159211098
|z (OCoLC)1201804423
|
| 050 |
|
4 |
|a RM331
|b .P53 2020
|
| 060 |
|
4 |
|a WB 330
|
| 082 |
0 |
4 |
|a 615.5
|2 23
|
| 245 |
0 |
0 |
|a Placebo effects in neurologic disease /
|c edited by Natalie P. Witek, Christopher G. Goetz, Glenn T. Stebbins.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2020.
|
| 264 |
|
4 |
|c �2020
|
| 300 |
|
|
|a 1 online resource (xii, 266 pages) :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 153
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
8 |
|
|a Intro -- Placebo Effects in Neurologic Disease -- Copyright -- Contents -- Contributors -- Preface -- Part 1: Background and methods in placebo -- Chapter One: Better than nothing: A historical account of placebos and placebo effects from modern to contemporary medicine -- 1. Introduction -- 2. The etymology of ``placebo�� and its first recorded use in medicine (fourth century-1772) -- 3. Placebos as treatments in clinical practice (1772-1954) -- 4. Placebos as controls in scientific research (1772-1930s) -- 5. The ``Conferences on Therapy�� at Cornell University (1930s-1946)
|
| 505 |
8 |
|
|a 6. Beecher and the ``powerful placebo�� (1955) -- 7. The rise of RCTs and the first pioneering studies on placebo effects (1955-1970s) -- 8. The empirical study of placebo effects and the golden age of placebo research (1970s-) -- 9. Summary and conclusions -- Acknowledgment -- References -- Chapter Two: Determinants of placebo effects -- 1. Introduction -- 2. Intrinsic factors impacting placebo response -- 2.1. Neural systems involved in the placebo response -- 2.2. Patient-based determinants -- 2.2.1. Personality factors -- 2.2.2. Genetic factors -- 2.2.3. Environmental factors
|
| 505 |
8 |
|
|a 2.3. Clinician/researcher based determinants -- 2.3.1. Personality factors -- 2.3.2. Environmental factors -- 3. Extrinsic factors impacting placebo response -- 3.1. Study design -- 3.2. Advertising, branding, and exclusivity as enhancers of placebo effects -- 4. Culture -- 5. Future directions -- References -- Chapter Three: Strategies to minimize placebo effects in research investigations -- 1. Introduction -- 2. Concepts and definitions -- 3. Why may the placebo effect be detrimental in clinical trials? -- 4. The impact -- 5. Placebo effect in neurology
|
| 505 |
8 |
|
|a 6. Strategies to minimize the placebo effect in clinical trials -- 6.1. Study design -- 6.2. Statistical power -- 6.3. Patient selection -- 6.4. Allocation stratification -- 6.5. Outcomes and endpoints -- 6.6. Analysis -- 7. Challenges and future direction -- References -- Chapter Four: Maximizing placebo response in neurological clinical practice -- 1. Introduction -- 2. Why should placebo be maximized in the clinic? -- 3. How should placebo be maximized in the clinic? -- 3.1. Personalizing placebo response and utilizing predictors of placebo response
|
| 505 |
8 |
|
|a 3.2. Strategies that modulate expectations -- 3.3. Impact of learning -- 4. Future perspectives -- Funding -- Conflict of interest -- References -- Chapter Five: Statistical methods in handling placebo effect -- 1. Introduction -- 2. Trial designs -- 2.1. Designs to eliminate and/or reduce placebo response -- 2.2. Crossover study design -- 2.3. Placebo run-in and randomized withdrawal designs -- 2.4. Sequential parallel comparison design (SPCD) -- 2.5. Two-way enriched design (TED) -- 2.6. Designs to estimate placebo response -- 2.6.1. Delayed-start or randomized-start designs
|
| 588 |
0 |
|
|a Online resource; title from digital title page (viewed on July 15, 2020).
|
| 650 |
|
0 |
|a Placebos (Medicine)
|
| 650 |
|
0 |
|a Central nervous system
|x Diseases.
|
| 650 |
|
0 |
|a Nervous system
|x Diseases.
|
| 650 |
|
2 |
|a Placebo Effect
|0 (DNLM)D015990
|
| 650 |
|
2 |
|a Placebos
|0 (DNLM)D010919
|
| 650 |
|
2 |
|a Nervous System Diseases
|0 (DNLM)D009422
|
| 650 |
|
2 |
|a Central Nervous System Diseases
|0 (DNLM)D002493
|
| 650 |
|
6 |
|a Syst�eme nerveux central
|x Maladies.
|0 (CaQQLa)201-0011353
|
| 650 |
|
6 |
|a Effet placebo.
|0 (CaQQLa)201-0282694
|
| 650 |
|
6 |
|a Placebos.
|0 (CaQQLa)201-0047469
|
| 650 |
|
6 |
|a Syst�eme nerveux
|x Maladies.
|0 (CaQQLa)201-0007359
|
| 650 |
|
7 |
|a Nervous system
|x Diseases
|2 fast
|0 (OCoLC)fst01036098
|
| 650 |
|
7 |
|a Central nervous system
|x Diseases
|2 fast
|0 (OCoLC)fst00850732
|
| 650 |
|
7 |
|a Placebos (Medicine)
|2 fast
|0 (OCoLC)fst01732316
|
| 700 |
1 |
|
|a Witek, Natalie P.,
|e editor.
|
| 700 |
1 |
|
|a Goetz, Christopher G.,
|e editor.
|
| 700 |
1 |
|
|a Stebbins, Glenn T.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Placebo effects in neurologic disease.
|b First edition.
|d Cambridge, MA : Academic Press, 2020
|z 0128211180
|z 9780128211182
|w (OCoLC)1135669342
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 153.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/153
|z Texto completo
|
